Skip to main content

Table 1 Socio-demographic and clinical variables of the 114 patients with disability

From: Self-reported disability in women with fibromyalgia from a tertiary care center

  Mild (n = 13) Moderate (n = 54) Severe (n = 47) Total (n = 114) P value Size effect
Age in years 48.2 ± 5.9 49.9 ± 7.2 46.8 ± 6.4 48.4 ± 6.8 0.07 0.02a
Years of education 10 ± 3.5 10.2 ± 3.6 10.1 ± 3.2 10.1 ± 3.4 0.98 0.01a
Time since onset of pain (months) 48 (24) 48 (64) 36 (42) 48 (60) 0.22 0.02b
Time since FM diagnosis (months) 36 (46) 34 (36) 12 (36) 24 (42) 0.08 0.03b
Body mass index 29.1 ± 4.5 28.4 ± 3.1 28.9 ± 3.7 28.7 ± 3.5 0.72 0.01a
Pain Intensity 5.0 ± 2.3 6.2 ± 2.1 7.3 ± 1.6 6.5 ± 2.1 < 0.001 0.12a
Number of drugs 2.3 ± 1.1 2.12 ± 1.2 2.08 ± 1.2 2.1 ± 1.2 0.85 0.01a
Pharmacological treatment 11 [84.6] 49 [90.7] 39 [82.9] 99 [86.8] 0.49
 Celecoxib 5 [38.4] 21 [38.8] 9 [19.1] 35 [30.7] 0.08  
 Nonsteroidal anti-inflammatory drugs 3 [23.0] 9 [16.6] 13 [27.6] 25 [21.9] 0.41  
 Pregabalin or Gabapentin 6 [46.1] 30 [55.5] 24 [51.0] 60 [52.6] 0.79  
 Antidepressants 9 [69.2] 27 [50.0] 29 [61.7] 65 [57.0] 0.31  
 Tramadol-acetaminophen 5 [38.4] 19 [35.1] 13 [27.6] 37 [32.4] 0.64  
 Benzodiazepines 0 [0] 7 [12.9] 4 [8.5] 11 [9.6] 0.34  
 Quetiapine 0 [o] 0 [o] 2 [4.2] 2 [1.7] 0.23  
Medication adherence
 Non-pharmacological treatment 2 [15.3] 5 [9.2] 8 [17.0] 15 [13.0] 0.35  
 Adherent 5 [38.4] 26 [48.1] 17 [36.1] 48 [42.1]   
 Non-adherent 2 [15–3] 19 [35.1] 17 [36.1] 38 [33.0]   
 Unknown 4 [30.7] 4 [7.4] 5 [10.6] 13 [11.3]   
  1. Data. Mean ± Standard deviation; median (interquartile range); Frequency [percent]
  2. Interpretation. a Omega squared = 0.01–0.059 is a low association. 0.06–0.13 is a medium association. ≥0.14 is a large association. b Epsilon squared